Noom Launches Oral Medication Offering for Weight Loss
Noom will begin offering oral medications for weight loss, starting with Metformin. This can support those who have a needle version or have a lower body mass index than indicated for GLP-1s.
The Rapid Growth of GLP-1s and Their Impact on Bariatric Surgery
Bariatric surgery is still the gold standard for morbid obesity treatment, yet patients and medical professionals will likely seek less invasive weight loss drugs before considering bariatric surgery.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Can Herbal Alternatives Ease the Economic Burden of Weight Loss Drugs?
For patients who may be unable to afford the high cost of GLP-1 obesity drugs or are worried about the side effects, it's important for healthcare providers to offer education on herbal alternatives and consider these as part of the broader treatment conversation.
Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study
The weight loss results for the Terns Pharmaceuticals drug TERN-601 come from a four-week Phase 1 clinical trial. Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class.
Roche Weighs In With Encouraging Early Clinical Data for Oral GLP-1 Drug
Roche reported its oral GLP-1 agonist led to an average 6.1% weight loss at four weeks, according to preliminary results from part of a Phase 1 study. The small molecule comes from Roche’s $2.7 billion acquisition of Carmot Therapeutics last year.
Navigating Opportunities and Challenges in the GLP-1 Drug Gold Rush
GLP-1 agonists are transforming the weight loss market. Experts weighed in on the changes they’re seeing, speaking in a panel discussion during the MedCity News INVEST Conference in Chicago.
Reducing Clinical and Staff Burnout with AI Automation
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Balancing Weight-loss Medication Cost and Care
How employers are optimizing weight-loss medication cost and coverage
Novo Nordisk Obesity Pill Flashes the Potential to Beat Wegovy in Weight Loss
Novo Nordisk reported its weight loss pill amycretin led to greater weight loss measured at 12 weeks compared to clinical trial results for its blockbuster obesity drug Wegovy. But these results are from a small Phase 1 study and more testing is needed.
Viking Therapeutics Obesity Drug’s Data Raise Best-in-Class Expectations
The weight loss achieved by Viking Therapeutics’ obesity drug tops results posted by Eli Lilly’s Zepbound in its pivotal test. But Viking still needs to show its results can hold up in a larger Phase 3 clinical trial.
How Are Payers Approaching Obesity Management?
GLP-1s continue to be in high demand, and the healthcare industry is watching closely to see how payers decide to cover the drugs going forward. During a virtual panel, payer executives noted that it's important to remember that GLP-1s won’t be able to solve the country’s obesity crisis by themselves.
presented by
Transforming Patient Care: The Role of AI-Powered Assistants
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Why One CEO Thinks Drugs Won’t Be Able to Solve the Obesity Crisis
New research found that there are no racial disparities in weight loss results among patients taking obesity drugs. However, the study found that people of color have less access to services like behavioral care or surgical interventions, which are often needed in order for patients to lose weight and keep it off. To tackle this issue, Enara Health CEO Rami Bailony argued that the U.S. healthcare system must innovate the way it dispenses weight loss drugs, employing a more holistic care approach.
Zocdoc CEO Predicts 5 Ways Patient Behavior Will Change in 2024
Zocdoc Founder and CEO Oliver Kharraz gave five predictions about how patient preferences will evolve in 2024. Some of them include Americans increasingly seeking cash-pay care options and an uptick in patients seeking mental health appointments before and after the presidential election.
Amazon Exec: We Love Innovation, But We Don’t Love to Talk About Who Pays for It
It’s easy to get caught up in the excitement surrounding innovations in the medical field, Amazon Pharmacy Chief Medical Officer Dr. Vin Gupta noted. But when talking about these innovations, healthcare leaders often fail to address questions about whether they will be covered by insurance and whether all patients will be able to benefit from them, he pointed out.
Walgreens Exec: Reimbursement Models Need to Catch Up with GLP-1 Demand
Walgreens is seeing “an enormous amount of demand” for injectable weight loss drugs, its president of U.S. healthcare said during the Reuters Total Health conference in Chicago. He declared that the healthcare industry needs to come up with a reimbursement model “that correctly compensates pharmacists and others” to administer these drugs. In his view, reimbursement hasn't caught up with the demand.
FDA Approves Eli Lilly Weight Drug, Now Set to Compete Against Novo’s Wegovy
Eli Lilly weight management drug Zepbound landed its much anticipated FDA approval. The new Lilly product is in the same drug class as Novo Nordisk weight medication Wegovy, but it offers an additional mechanism of action and costs less.